First Berlin Equity Research publishes independent analysis of Cyxone

Cyxone (publ), a biotech company in autoimmune diseases, announces today that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.

The independent analysis covers the first quarter of 2022 and was published on 16 May 2022.

The report in English can be read in its entirety on the Cyxone’s website.

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. For more information, please visit www.cyxone.com